Trial NCT02326805

PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Major Program(s) or Research Group(s)

  • Phase 0/I/II Cancer Prevention Clinical Trials Program
  • Prostate and Urologic Cancer

Sponsor

National Cancer Institute (NCI)

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT02326805

This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen
[PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer
undergoing active surveillance. Vaccines made from a person's tumor cells may help the body
build an effective immune response to kill tumor cells that express PSA.

Intervention

Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec

Condition

Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7

Investigators

John K Parsons

See list of participating sites